Long-term epidemiology of neonatal sepsis: Benefits and concerns: Commentary on van den Hoogen A, et al.: Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents (Neonatology 2010;97:22-28)

Neonatology

Volumn 97, Issue 1, 2009, Pages 29-30

  Sherman, Michael P ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; CANDIDIASIS; CLINICAL DECISION MAKING; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; GROUP B STREPTOCOCCAL INFECTION; HOSPITAL INFECTION; HUMAN; MORBIDITY; NECROTIZING ENTEROCOLITIS; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SEPSIS; NONHUMAN; NOTE; ONSET AGE; PREMATURITY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT, NEWBORN; MASSACHUSETTS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 67649429490     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000226605     Document Type: Note

References (13)

1. Bizzarro MJ, Raskind C, Baltimore RS, Gallagher PG: Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005; 116: 595-602.
2. van den Hoogen A, Gerards LJ, Verboon- Maciolek MA, Fleer A, Krediet TG: Longterm trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents. Neonatology 2010;97:22-28.
3. Baltimore RS: Consequences of prophylaxis for group B streptococcal infections of the neonate. Semin Perinatol 2007; 31: 33-38.
4. Bizzarro MJ, Dembry LM, Baltimore RS, Gallagher PG: Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008; 121: 689-696.
5. Curtis C, Shetty N: Recent trends and prevention of infection in the neonatal intensive care unit. Curr Opin Infect Dis 2008; 21: 350-356.
6. Gray JW: Surveillance of infection in neonatal intensive care units. Early Hum Dev 2007; 83: 1571-11563
7. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ: Antimicrobial use and the influence of inadequate empiric antimicrobial therapy on the outcomes of nosocomial infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2004; 25: 735-741.
8. Adams-Chapman I, Stoll BJ: Neonatal infection and long-term neurodevelopmental outcome in the preterm infant. Curr Opin Infect Dis 2006; 19: 290-297.
9. Karlowicz MG, Buescher ES, Surka AE: Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics 2000; 106: 1387-1390.
10. Cotton CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr; and on behalf of the National Institutes for Child Health and Human Development Neonatal Research Network: The association of third generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006; 118: 717-722.
11. Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T; National Nosocomial Infections Surveillance System Hospitals: Changing incidence of candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117: 1680-1687.
12. Carey AJ, Saiman L, Polin RA: Hospital-acquired infections in the NICU: Epidemiology for the new millennium. Clin Perinatol 2008; 35: 223-249.
13. Kaufman D: Strategies for prevention of neonatal invasive candidiasis. Semin Perinatol 2003; 27: 414-424.